Amari Shoichiro, Shahrook Sadequa, Namba Fumihiko, Ota Erika, Mori Rintaro
Neonatology, National Center for Child Health and Development, Tokyo, Japan.
Hamilton Health Sciences, Hamilton, Canada.
Cochrane Database Syst Rev. 2020 Oct 2;10(10):CD012273. doi: 10.1002/14651858.CD012273.pub2.
Branched-chain amino acids (BCAAs) play a vital role in neonatal nutrition. Optimal BCAA supplementation might improve neonatal nutrient storage, leading to better physical and neurological development and other outcomes.
To determine the effect of BCAA supplementation on physical growth and neurological development in term and preterm neonates. We planned to make the following comparisons: parenteral nutrition with and without BCAA supplementation; enteral BCAA supplementation versus no supplementation; and any type of supplementation including enteral, parenteral and both ways versus no supplementation. To investigate the supplementation effectiveness for different dosages assessed in the eligible trials.
We conducted comprehensive searches using Cochrane Neonatal's standard search strategies: Cochrane Central Register of Controlled Trials (CENTRAL 2016, Issue 6), MEDLINE, Embase and CINAHL (up to July 2016). We updated the search with CENTRAL (2019, Issue 8), MEDLINE, Embase and CINAHL (up to August 2019). We also searched clinical trials registries and reference lists of retrieved articles.
We planned to include individual and cluster-randomised and quasi-randomised controlled trials comparing BCAA supplementation versus placebo or no supplementation in term and preterm neonates. We excluded trials presented only as abstracts and cross-over trials.
Two review authors independently assessed the eligibility of all potential studies identified from the search strategy. We planned to extract data using a pilot-tested standard data extraction form and assess risk of bias of the included studies following the methods described in the Cochrane Handbook for Systematic Reviews of Interventions. We planned to analyse treatment effects and report their effect estimates as per dichotomous or continuous data with 95% confidence intervals. We planned to conduct subgroup analysis to investigate heterogeneity, and perform sensitivity analysis where possible. We planned to use fixed-effect meta-analysis to combine data wherever appropriate. We planned to assess evidence quality using the GRADE approach.
We did not identify any potentially eligible studies that met the inclusion criteria in this review.
AUTHORS' CONCLUSIONS: We found no trial data to support or refute the idea that BCAA supplementation affects physical and neurological development and other outcomes in term and preterm neonates.
支链氨基酸（BCAAs）在新生儿营养中起着至关重要的作用。最佳的BCAA补充可能会改善新生儿的营养储存，从而带来更好的身体和神经发育以及其他结果。
确定补充BCAA对足月儿和早产儿身体生长和神经发育的影响。我们计划进行以下比较：补充BCAA与不补充BCAA的肠外营养；补充肠内BCAA与不补充；以及任何类型的补充（包括肠内、肠外和两种方式）与不补充。调查符合条件的试验中评估的不同剂量的补充效果。
我们使用Cochrane新生儿的标准检索策略进行了全面检索：Cochrane对照试验中心注册库（CENTRAL 2016年第6期）、MEDLINE、Embase和CINAHL（截至2016年7月）。我们使用CENTRAL（2019年第8期）、MEDLINE、Embase和CINAHL（截至2019年8月）更新了检索。我们还检索了临床试验注册库和检索到的文章的参考文献列表。
我们计划纳入个体和整群随机以及半随机对照试验，比较补充BCAA与安慰剂或不补充BCAA对足月儿和早产儿的影响。我们排除仅以摘要形式呈现的试验和交叉试验。
两位综述作者独立评估了从检索策略中识别出的所有潜在研究的 eligibility。我们计划使用经过预试验的标准数据提取表提取数据，并按照《Cochrane干预系统评价手册》中描述的方法评估纳入研究的偏倚风险。我们计划分析治疗效果，并根据二分法或连续数据以95%置信区间报告其效应估计值。我们计划进行亚组分析以调查异质性，并在可能的情况下进行敏感性分析。我们计划在适当的情况下使用固定效应荟萃分析来合并数据。我们计划使用GRADE方法评估证据质量。
在本综述中，我们未识别出任何符合纳入标准的潜在合格研究。
我们没有发现试验数据支持或反驳补充BCAA会影响足月儿和早产儿的身体和神经发育以及其他结果这一观点。
